Exclusive: Sanofi Stops Enrolling COVID-19 Patients in Hydroxychloroquine Trials

May 29, 2020

(Reuters) – Sanofi has temporarily stopped recruiting new COVID-19 patients for two clinical trials on hydroxychloroquine and will no longer supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up, it said on Friday.  The moves come after the World Health Organization paused its large trial of hydroxychloroquine, prompting several European governments to ban the use of the drug, also used in rheumatoid arthritis and lupus.